Advertisement

Index by author

May 01, 1996; Volume 49,Issue 5

A

  1. Anderson, L M

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

B

  1. Balzarini, J

    1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
      J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson
      Molecular Pharmacology May 1996, 49 (5) 882-890;

  2. Barnes, P J

    1. Transforming growth factor-beta 1 induces transcriptional down-regulation of m2 muscarinic receptor gene expression.
      E B Haddad, J Rousell, J C Mak and P J Barnes
      Molecular Pharmacology May 1996, 49 (5) 781-787;

  3. Barret, J M

    1. DNA repair activity in protein extracts of fresh human malignant lymphoid cells.
      J M Barret, P Calsou, G Laurent and B Salles
      Molecular Pharmacology May 1996, 49 (5) 766-771;

  4. Beere, H M

    1. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
      H M Beere, C M Chresta and J A Hickman
      Molecular Pharmacology May 1996, 49 (5) 842-851;

  5. Billings, R E

    1. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450.
      T J Carlson and R E Billings
      Molecular Pharmacology May 1996, 49 (5) 796-801;

  6. Birrer, M J

    1. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
      A J Freemerman, A J Turner, M J Birrer, E Szabo, K Valerie and S Grant
      Molecular Pharmacology May 1996, 49 (5) 788-795;

  7. Bonner, T I

    1. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2.
      Z H Song and T I Bonner
      Molecular Pharmacology May 1996, 49 (5) 891-896;

  8. Boyd, N D

    1. Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
      D MacDonald, S C Silberman, J A Lowe, S E Drozda, S E Leeman and N D Boyd
      Molecular Pharmacology May 1996, 49 (5) 808-813;

C

  1. Calsou, P

    1. DNA repair activity in protein extracts of fresh human malignant lymphoid cells.
      J M Barret, P Calsou, G Laurent and B Salles
      Molecular Pharmacology May 1996, 49 (5) 766-771;

  2. Camarasa, M J

    1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
      J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson
      Molecular Pharmacology May 1996, 49 (5) 882-890;

  3. Carlson, T J

    1. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450.
      T J Carlson and R E Billings
      Molecular Pharmacology May 1996, 49 (5) 796-801;

  4. Caruncho, H

    1. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
      F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti
      Molecular Pharmacology May 1996, 49 (5) 822-831;

  5. Castanon, N

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;

  6. Cederbaum, A I

    1. Expression of cytochrome P4502E1 in rat fetal hepatocyte culture.
      D Wu and A I Cederbaum
      Molecular Pharmacology May 1996, 49 (5) 802-807;
    2. 1-Hydroxyethyl radical formation during NADPH- and NADH-dependent oxidation of ethanol by human liver microsomes.
      D N Rao, M X Yang, J M Lasker and A I Cederbaum
      Molecular Pharmacology May 1996, 49 (5) 814-821;

  7. Chauveau, J

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;

  8. Chaveau, J

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;

  9. Chen, J S

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  10. Chesselet, M F

    1. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study.
      M B Ghasemzadeh, S Sharma, D J Surmeier, J H Eberwine and M F Chesselet
      Molecular Pharmacology May 1996, 49 (5) 852-859;

  11. Chresta, C M

    1. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
      H M Beere, C M Chresta and J A Hickman
      Molecular Pharmacology May 1996, 49 (5) 842-851;

  12. Costa, E

    1. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
      F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti
      Molecular Pharmacology May 1996, 49 (5) 822-831;

D

  1. Davis, C D

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  2. De Clercq, E

    1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
      J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson
      Molecular Pharmacology May 1996, 49 (5) 882-890;

  3. Drewe, J A

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  4. Drozda, S E

    1. Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
      D MacDonald, S C Silberman, J A Lowe, S E Drozda, S E Leeman and N D Boyd
      Molecular Pharmacology May 1996, 49 (5) 808-813;

E

  1. Eberwine, J H

    1. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study.
      M B Ghasemzadeh, S Sharma, D J Surmeier, J H Eberwine and M F Chesselet
      Molecular Pharmacology May 1996, 49 (5) 852-859;

  2. el-Naggar, A K

    1. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
      Y H Ling, A K el-Naggar, W Priebe and R Perez-Soler
      Molecular Pharmacology May 1996, 49 (5) 832-841;

F

  1. Fletcher, G H

    1. Ability of nondepolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors.
      G H Fletcher and J H Steinbach
      Molecular Pharmacology May 1996, 49 (5) 938-947;

  2. Fornwald, L W

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  3. Freemerman, A J

    1. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
      A J Freemerman, A J Turner, M J Birrer, E Szabo, K Valerie and S Grant
      Molecular Pharmacology May 1996, 49 (5) 788-795;

  4. Fritschy, J M

    1. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
      F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti
      Molecular Pharmacology May 1996, 49 (5) 822-831;

G

  1. Gee, K W

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  2. Ghasemzadeh, M B

    1. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study.
      M B Ghasemzadeh, S Sharma, D J Surmeier, J H Eberwine and M F Chesselet
      Molecular Pharmacology May 1996, 49 (5) 852-859;

  3. Goto, M

    1. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B.
      M Goto, K Yamada, K Katayama and I Tanaka
      Molecular Pharmacology May 1996, 49 (5) 860-873;

  4. Grant, S

    1. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
      A J Freemerman, A J Turner, M J Birrer, E Szabo, K Valerie and S Grant
      Molecular Pharmacology May 1996, 49 (5) 788-795;

  5. Guerra, L

    1. Interaction of full and partial agonists of the A1 adenosine receptor with receptor/G protein complexes in rat brain membranes.
      A Lorenzen, L Guerra, H Vogt and U Schwabe
      Molecular Pharmacology May 1996, 49 (5) 915-926;

  6. Guidotti, A

    1. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
      F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti
      Molecular Pharmacology May 1996, 49 (5) 822-831;

H

  1. Haddad, E B

    1. Transforming growth factor-beta 1 induces transcriptional down-regulation of m2 muscarinic receptor gene expression.
      E B Haddad, J Rousell, J C Mak and P J Barnes
      Molecular Pharmacology May 1996, 49 (5) 781-787;

  2. Hawkinson, J E

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  3. Hen, R

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;

  4. Hickman, J A

    1. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
      H M Beere, C M Chresta and J A Hickman
      Molecular Pharmacology May 1996, 49 (5) 842-851;

  5. Hill, S J

    1. Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor.
      K E McCrea and S J Hill
      Molecular Pharmacology May 1996, 49 (5) 927-937;

  6. Hoffman, B B

    1. Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: role of beta gamma subunits in transducing enhanced activity of the type VI isoform.
      J M Thomas and B B Hoffman
      Molecular Pharmacology May 1996, 49 (5) 907-914;

  7. Hogenkamp, D J

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

I

  1. Impagnatiello, F

    1. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
      F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti
      Molecular Pharmacology May 1996, 49 (5) 822-831;

K

  1. Karlsson, A

    1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
      J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson
      Molecular Pharmacology May 1996, 49 (5) 882-890;

  2. Katayama, K

    1. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B.
      M Goto, K Yamada, K Katayama and I Tanaka
      Molecular Pharmacology May 1996, 49 (5) 860-873;

  3. Kimbrough, C L

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  4. Konopa, J

    1. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
      A Skladanowski, S Y Plisov, J Konopa and A K Larsen
      Molecular Pharmacology May 1996, 49 (5) 772-780;

L

  1. Lan, N C

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  2. Larsen, A K

    1. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
      A Skladanowski, S Y Plisov, J Konopa and A K Larsen
      Molecular Pharmacology May 1996, 49 (5) 772-780;

  3. Lasker, J M

    1. 1-Hydroxyethyl radical formation during NADPH- and NADH-dependent oxidation of ethanol by human liver microsomes.
      D N Rao, M X Yang, J M Lasker and A I Cederbaum
      Molecular Pharmacology May 1996, 49 (5) 814-821;

  4. Laurent, G

    1. DNA repair activity in protein extracts of fresh human malignant lymphoid cells.
      J M Barret, P Calsou, G Laurent and B Salles
      Molecular Pharmacology May 1996, 49 (5) 766-771;

  5. Leeman, S E

    1. Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
      D MacDonald, S C Silberman, J A Lowe, S E Drozda, S E Leeman and N D Boyd
      Molecular Pharmacology May 1996, 49 (5) 808-813;

  6. Levy, G N

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  7. Ling, Y H

    1. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
      Y H Ling, A K el-Naggar, W Priebe and R Perez-Soler
      Molecular Pharmacology May 1996, 49 (5) 832-841;

  8. Longone, P

    1. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
      F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti
      Molecular Pharmacology May 1996, 49 (5) 822-831;

  9. Lorenzen, A

    1. Interaction of full and partial agonists of the A1 adenosine receptor with receptor/G protein complexes in rat brain membranes.
      A Lorenzen, L Guerra, H Vogt and U Schwabe
      Molecular Pharmacology May 1996, 49 (5) 915-926;

  10. Lowe, J A

    1. Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
      D MacDonald, S C Silberman, J A Lowe, S E Drozda, S E Leeman and N D Boyd
      Molecular Pharmacology May 1996, 49 (5) 808-813;

M

  1. MacDonald, D

    1. Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
      D MacDonald, S C Silberman, J A Lowe, S E Drozda, S E Leeman and N D Boyd
      Molecular Pharmacology May 1996, 49 (5) 808-813;

  2. Macor, J E

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;

  3. Mak, J C

    1. Transforming growth factor-beta 1 induces transcriptional down-regulation of m2 muscarinic receptor gene expression.
      E B Haddad, J Rousell, J C Mak and P J Barnes
      Molecular Pharmacology May 1996, 49 (5) 781-787;

  4. McCrea, K E

    1. Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor.
      K E McCrea and S J Hill
      Molecular Pharmacology May 1996, 49 (5) 927-937;

  5. Moskowitz, M A

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;

N

  1. Nerurkar, P V

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

P

  1. Pelemans, H

    1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
      J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson
      Molecular Pharmacology May 1996, 49 (5) 882-890;

  2. Pérez-Pérez, M J

    1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
      J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson
      Molecular Pharmacology May 1996, 49 (5) 882-890;

  3. Perez-Soler, R

    1. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
      Y H Ling, A K el-Naggar, W Priebe and R Perez-Soler
      Molecular Pharmacology May 1996, 49 (5) 832-841;

  4. Pesold, C

    1. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
      F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti
      Molecular Pharmacology May 1996, 49 (5) 822-831;

  5. Plisov, S Y

    1. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
      A Skladanowski, S Y Plisov, J Konopa and A K Larsen
      Molecular Pharmacology May 1996, 49 (5) 772-780;

  6. Priebe, W

    1. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
      Y H Ling, A K el-Naggar, W Priebe and R Perez-Soler
      Molecular Pharmacology May 1996, 49 (5) 832-841;

R

  1. Rao, D N

    1. 1-Hydroxyethyl radical formation during NADPH- and NADH-dependent oxidation of ethanol by human liver microsomes.
      D N Rao, M X Yang, J M Lasker and A I Cederbaum
      Molecular Pharmacology May 1996, 49 (5) 814-821;

  2. Rice, J M

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  3. Riggs, C W

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  4. Rousell, J

    1. Transforming growth factor-beta 1 induces transcriptional down-regulation of m2 muscarinic receptor gene expression.
      E B Haddad, J Rousell, J C Mak and P J Barnes
      Molecular Pharmacology May 1996, 49 (5) 781-787;

S

  1. Salles, B

    1. DNA repair activity in protein extracts of fresh human malignant lymphoid cells.
      J M Barret, P Calsou, G Laurent and B Salles
      Molecular Pharmacology May 1996, 49 (5) 766-771;

  2. San-Félix, A

    1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
      J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson
      Molecular Pharmacology May 1996, 49 (5) 882-890;

  3. Scearce, K

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;

  4. Schut, H A

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  5. Schwabe, U

    1. Interaction of full and partial agonists of the A1 adenosine receptor with receptor/G protein complexes in rat brain membranes.
      A Lorenzen, L Guerra, H Vogt and U Schwabe
      Molecular Pharmacology May 1996, 49 (5) 915-926;

  6. Sharma, S

    1. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study.
      M B Ghasemzadeh, S Sharma, D J Surmeier, J H Eberwine and M F Chesselet
      Molecular Pharmacology May 1996, 49 (5) 852-859;

  7. Shen, K Z

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  8. Silberman, S C

    1. Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
      D MacDonald, S C Silberman, J A Lowe, S E Drozda, S E Leeman and N D Boyd
      Molecular Pharmacology May 1996, 49 (5) 808-813;

  9. Skladanowski, A

    1. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
      A Skladanowski, S Y Plisov, J Konopa and A K Larsen
      Molecular Pharmacology May 1996, 49 (5) 772-780;

  10. Snyderwine, E G

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  11. Song, Z H

    1. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2.
      Z H Song and T I Bonner
      Molecular Pharmacology May 1996, 49 (5) 891-896;

  12. Steinbach, J H

    1. Ability of nondepolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors.
      G H Fletcher and J H Steinbach
      Molecular Pharmacology May 1996, 49 (5) 938-947;

  13. Surmeier, D J

    1. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study.
      M B Ghasemzadeh, S Sharma, D J Surmeier, J H Eberwine and M F Chesselet
      Molecular Pharmacology May 1996, 49 (5) 852-859;

  14. Szabo, E

    1. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
      A J Freemerman, A J Turner, M J Birrer, E Szabo, K Valerie and S Grant
      Molecular Pharmacology May 1996, 49 (5) 788-795;

T

  1. Tanaka, I

    1. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B.
      M Goto, K Yamada, K Katayama and I Tanaka
      Molecular Pharmacology May 1996, 49 (5) 860-873;

  2. Thomas, J M

    1. Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: role of beta gamma subunits in transducing enhanced activity of the type VI isoform.
      J M Thomas and B B Hoffman
      Molecular Pharmacology May 1996, 49 (5) 907-914;

  3. Thorgeirsson, S S

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  4. Turner, A J

    1. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
      A J Freemerman, A J Turner, M J Birrer, E Szabo, K Valerie and S Grant
      Molecular Pharmacology May 1996, 49 (5) 788-795;

V

  1. Valerie, K

    1. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
      A J Freemerman, A J Turner, M J Birrer, E Szabo, K Valerie and S Grant
      Molecular Pharmacology May 1996, 49 (5) 788-795;

  2. Vogt, H

    1. Interaction of full and partial agonists of the A1 adenosine receptor with receptor/G protein complexes in rat brain membranes.
      A Lorenzen, L Guerra, H Vogt and U Schwabe
      Molecular Pharmacology May 1996, 49 (5) 915-926;

W

  1. Waeber, C

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;

  2. Weber, W W

    1. Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
      P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy
      Molecular Pharmacology May 1996, 49 (5) 874-881;

  3. Whittemore, E R

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  4. Woodward, R M

    1. 3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
      J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward
      Molecular Pharmacology May 1996, 49 (5) 897-906;

  5. Wu, D

    1. Expression of cytochrome P4502E1 in rat fetal hepatocyte culture.
      D Wu and A I Cederbaum
      Molecular Pharmacology May 1996, 49 (5) 802-807;

Y

  1. Yamada, K

    1. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B.
      M Goto, K Yamada, K Katayama and I Tanaka
      Molecular Pharmacology May 1996, 49 (5) 860-873;

  2. Yang, M X

    1. 1-Hydroxyethyl radical formation during NADPH- and NADH-dependent oxidation of ethanol by human liver microsomes.
      D N Rao, M X Yang, J M Lasker and A I Cederbaum
      Molecular Pharmacology May 1996, 49 (5) 814-821;

  3. Yu, X J

    1. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
      X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau
      Molecular Pharmacology May 1996, 49 (5) 761-765;
Back to top

In this issue